Procedures’ costs related to outpatient chemotherapy treatment of women suffering from breast cancer by Nobrega, Caroline Rife & Lima, Antônio Fernandes Costa
699Nobrega CR, Lima AFC
Rev Esc Enferm USP
2014; 48(4):699-705
www.ee.usp.br/reeusp/
Procedures costs related to outpatient chemotherapy 
treatment of women suffering from breast cancer
RESUmEn 
Objetivo: Identificar el costo directo de los 
procedimientos relacionados con el trata-
miento de quimioterapia ambulatoria para 
las mujeres con cáncer de mama. Método: 
Investigación cuantitativa, del tipo de es-
tudio de caso, realizada en el ambulatorio 
de  quimioterapia de un hospital privado Se 
calculó el costo total mediante la multipli-
cación del tiempo dedicado por los profe-
sionales involucrados en el  proceso, por el 
costo unitario de la mano de obra directa, 
sumándose al costo de los materiales, fár-
macos y soluciones. Para la realización de 
los cálculos se utilizó la moneda brasileña 
(R$). Resultados: El costo total medio, por 
sesión de quimioterapia, correspondió a R$ 
1.783,01 (100%), de los cuales R$ 1.671,66 
(93,75%) fueron con fármacos, R$ 74,98 
(4,21%) con materiales, R$ 28,49 (1,60%) 
con mano de obra y R$ 7,88 (0,44%) con 
soluciones. Conclusión: Los resultados lo-
grados podrán servir como base para las 
discusiones y la toma de decisiones con 
respecto a la gestión de los costos relacio-
nados con la quimioterapia, con vistas a la 
reducción de los gastos y la eliminación de 
los desperdicios, sin perjuicios a la atenci-
ón prestada. 
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RESUmo 
Objetivo: Identificar o custo direto de pro-
cedimentos relacionados ao tratamento 
quimioterápico ambulatorial de mulheres 
portadoras de câncer de mama. Método: 
Pesquisa quantitativa, do tipo estudo de 
caso, realizada no ambulatório de qui-
mioterapia de um hospital privado. O 
custo total foi calculado multiplicando-se 
o tempo despendido pelos profissionais 
envolvidos nos procedimentos terapêu-
ticos, pelo custo unitário da mão de obra 
direta, somando-se ao custo dos materiais, 
fármacos e soluções. Para a realização dos 
cálculos, utilizou-se a moeda brasileira 
(R$). Resultados: O custo total médio, por 
sessão de quimioterapia, correspondeu 
a R$ 1.783,01 (100%), sendo R$ 1.671,66 
(93,75%) com fármacos, R$ 74,98 (4,21%) 
com materiais, R$ 28,49 (1,60%) com mão 
de obra e R$ 7,88 (0,44%) com soluções. 
Conclusão: Os resultados obtidos poderão 
subsidiar discussões e tomadas de deci-
sões em relação à gestão dos custos rela-
tivos à quimioterapia visando à redução 
dos gastos e a eliminação dos desperdícios, 
sem prejuízos ao atendimento prestado. 
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AbStRAct 
Objective: To identify the direct cost 
of procedures related to an outpatient 
chemotherapy treatment for women 
with breast cancer. Method: This is a 
quantitative research, using the case study 
methodology, performed in an outpatient 
chemotherapy of a private hospital. The 
total cost was calculated by multiplying 
the time spent by professionals involved 
in therapeutic procedures, the unit cost of 
direct labor, adding to the cost of materials, 
drugs and solutions. For performing the 
calculations, we used the Brazilian currency 
(R$). Results: The average total cost per 
chemotherapy session corresponded to 
R$ 1,783.01 (100%), being R$ 1,671.66 
(93.75%) spent with drugs, R$ 74,98 
(4.21%) with materials, R$ 28.49 (1.60%) 
with labor and R$ 7.88 (0.44%) with 
solutions. Conclusion: The results may 
support discussions and decision making 
for the management of costs related to 
chemotherapy aimed at reducing expenses 
and eliminating waste without harm to the 
care provided.  
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intRodUção
Questions regarding costs for the treatment of can-
cer have been one of the agendas of discussions in many 
countries. The American Society of Clinical Oncology (AS-
CO), considering the high cost that involves this type of 
treatment and the inability of many Americans to perform 
them, have developed strategies to discuss the factors 
that contribute to rising costs. According to the ASCO(1), 
high quality cancer treatment will be increasingly less ac-
cessible to an increasing number of cancer patients, un-
less actions are taken to reverse current trends, which 
have intensified concern about the financial aspects. 
Anticancer treatments represent a high cost for the 
Brazilian health systems, both for the Unified Health Sys-
tem (SUS) as for the Supplementary Health System (SHS)(2). 
SHS managers recognize that the cost of antineoplastic 
therapy has been growing alarmingly and seek alterna-
tives to minimize its costs(3). 
American study addressing the costs of health care for 
patients with metastatic breast cancer showed that che-
motherapy throughout 18 months represented 25% of to-
tal costs, totaling U$ 128.556 dollars per patient(4). 
In relation to chemotherapy of breast cancer, a single 
drug may be used or several of them associated with the 
choice of anticancer regimens, such as CMF (Cyclophos-
phamide, Methotrexate and Fluorouracil); DCP (Doxorubi-
cin, Cyclophosphamide and Paclitaxel); FEC (Fluorouracil, 
Epirubicin and Cyclophosphamide) and FDC (Fluoroura-
cil, Doxorubicin and Cyclophosphamide)(5). However, it 
is worth noting that although there are frequently used 
regimens, there are numerous possible combinations be-
tween the various antineoplastic availability(6). 
In Brazil, there are few studies addressing costs in the 
area of  Oncology, a complex discipline that combines thera-
peutic procedures using high technology and skilled labor 
in order to improve the quality of life and survival rates of 
cancer patients. To contribute to the development of knowl-
edge in this thematic, the present study aimed to identify the 
average total cost procedures related to outpatient chemo-
therapy for women with breast cancer at a private hospital.
mEtHod
This is a quantitative, exploratory, descriptive, case 
study type(7), conducted in an Outpatient Chemotherapy 
clinic in a private hospital of large size, in the city of São 
Paulo (SP), Brazil, which currently holds, most frequently, 
the treatment of individuals with breast and bowel cancers. 
The hospital has an Outpatient Unit for Social Sustainabil-
ity in order to host the project management in partnership 
with the Ministry of Health (MH) and serve public patients. 
Thus, patients with breast cancer may come from this unit, 
from health insurance companies or private payment. 
The outpatient clinic is open from 8:00am to 6:00pm, 
Monday through Friday and serves an average of 25 pa-
tients per day. The health care team consists of six medi-
cal oncologists, four nurses, two pharmaceutical profes-
sionals, one nursing technician and a pharmacy assistant. 
The most commonly used anticancer regimens are 
CMF; DCP; FDC and FEC, they may use various other com-
binations of drugs, for instance, Docetaxel, Trastuzumab, 
Bevacizumab, Gemcitabine and Vinorelbined. The appli-
cations of the regimes and combinations of drugs can be 
weekly, with intervals of 21 or 28 days. 
The procedures related to chemotherapy treatment, 
that composed this study, were: separation, preparation 
and disposal of chemotherapeutics (first stage); separa-
tion and disposal venipuncture materials and pre-medi-
cation (second stage); preparation and administration of 
pre-medication (third stage); administration of chemo-
therapeutics (fourth stage) and removal of vascular ac-
cess/disposal of chemotherapeutic wastes (fifth stage). 
Due to limitation of time for conducting the study, it was 
not possible to observe the stage surveillance of nurses 
during the administration of chemotherapy. 
At the Outpatient Clinic, the working process of the 
pharmaceutical professional comprises the preparation 
and disposal of chemotherapeutics, and the pharmacy 
assistant should separate and dispense venipuncture ma-
terials and pre-medications (antihistamines, antiemetics, 
and corticosteroids). It is the responsibility of nurses and 
nursing technicians, the preparation of pre-medication, 
puncture of peripheral venous access and administra-
tion of pre-medication. However, it belongs exclusively to 
nurses puncture of central access port-a-cath and the ad-
ministration of chemotherapeutics. 
The sample was based on convenience, non-probabil-
ity, and corresponded to 60 horizontal observations from 
the first to the fifth stage, conducted from November 
2012 to March 2013. 
To subsidize the cost calculation per chemotherapy 
session, the consumption of materials, drugs and solu-
tions were documented, as well as the category, the num-
ber of professionals involved and the time spent in each 
process steps. The time spent by these professionals was 
recorded using a stopwatch. 
We calculated the unit cost of direct labor from the aver-
age salaries provided by the Human Resources Hospital De-
partment, being: pharmaceutical professional - R$ 5,994.91 
(R$ 0.57/minute); pharmacy assistant - R$ 2,118.75 (R$ 
0.20/minute); Nurse - R$ 8,786.72 (R$ 0.92/minute) and 
nursing technician - R$ 5,823.29 (R$ 0.61/minute). 
Costs were measured using the direct costs, which can 
be clearly identified and quantified(8). Then, we calculated 
the average total cost per chemotherapy session, by mul-
tiplying the time spent (timed) by professionals at a unit 
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cost of direct labor, adding to the cost of materials, drugs 
and solutions. For performing the calculations, we used 
the Brazilian currency1 (R$). 
The study was approved by the Ethics and Research 
Committee of the School of Nursing, University of São Pau-
lo (CAAE: 06246612.7.0000.5392; Review: 123,161) and 
the Hospital field of study (CAAE: 06246612.7.0000.5392; 
Review: 129,104). 
RESULtS 
The observed procedures were related to 32 women, 
aged 39-88 years, mean age 56.95 (SD± 9.88), mode of 58 
years (95% CI: 54.40 - 59.50). The observation of a single 
patient ranged from one to six times, one (56.25%) and 
two (25%) times the most frequent occurrences. 
In the first step: separation, preparation and disposal of 
chemotherapeutics, the  most used drugs were Paclitaxel 
(41.67%) and the antineoplastic regimen Doxorubicin + Cy-
clophosphamide (35%). It is evident that Trastuzumab (unit 
value of R$ 8,441.67) and Paclitaxel (unit value of R$ 673.34 
- 100mg and  R$ 344.95 - 30mg) represented the most signifi-
cant values for the composition of the cost items. 
Among the materials used, the Neutrapur equipment had 
the highest unit cost (R$ 52.39), a unit has been used in 26 of 
60 observations. As for the solutions (distilled water, water for 
injection, saline solution), none showed significant unit value. 
The duration of the first stage ranged from 6.49 to 43.04 
minutes with a mean of 15.15 (SD± 6.84). In Table 1, we 
found that the average total cost was R$ 1,673.35 (100%), 
being 0.52% with pharmaceutical labor, 2.17% with materi-
als , 0.20% with solutions and 97.11% with drugs.
The second stage - disposal of pre-medications - ob-
tained the minimum duration of 1.15 minutes and maxi-
mum of 8.18 minutes, mean 3.38 (SD±1.56 minutes). The 
cost of direct labor of pharmacy assistant, single profes-
sional who participated in this stage ranged from R$ 0.23 
to R$ 1.64, and the average total cost of R$ 0.68 (SD±0.31). 
Table 1 – Distribution of observations on the first stage: separa-
tion, preparation and disposal of chemotherapeutics according to 
personnel costs, materials, solutions and drugs - São Paulo, SP, 
Brazil, 2013
Observations n Mean SD± Min Max Mode
Direct labor 
cost - pharma-
ceutical
60 8.64 3.9 3.7 24.53 ... 
Materials’ 
cost  60 36.39 31.84 4.33 74.95 72.33
Solutions’ 
cost  60 3.29 1.4 1.56 5.28 2.07
Drugs’ cost 60 1625.03 2771.53 74.4 9316.93 1077.18
Total Cost  60 1673.35 2765.4 99.38 9407.56 ... 
Table 2 – Distribution of observations on the stage, preparation 
and administration of pre medications according to personnel 
costs, materials, solutions and drugs - São Paulo, SP, Brazil, 2013 
Observations n Mean SD± Min Max Mode 
Direct labor cost   –   
preparation 60 5.22 1.79 1.17 10.55 ...
Direct labor cost   – 
administration 60 6.37 3.82 1.49 22.08 ...
Direct labor cost – 
Total (preparation 
and administration) 
60 11.59 4.67 5.15 28.92 ...
Materials’ cost 60 37.39 13.79 17.39 76.61 25.17
Solutions’ cost 60 4.47 1.77 1.46 7.02 2.92
Drugs’ cost 56 47.1 55.07 4.54 205.36 28.54
Total Cost 60 97.41 58.13 26.29 278.47 ...
In the third stage, the duration of the preparation of pre-
medication technique performed by nurses (33 observations) 
ranged from 4.24 to 15.07 minutes with a mean of 8.06 
(SD±2.33), and duration of preparations made by nurses 
(27 observations) ranged from 1.27 to 11.47 minutes with 
a mean of 6.06 (SD±2.32). Regarding the duration of admin-
istration of pre-medication technique performed by nurses 
(27 observations), there was a variation from 2.44 to 13.20 
minutes with a mean of 5.87 (SD±2.50), and duration of ad-
ministrations performed by nurses (33 observations) ranged 
from 3.47 to 24.00 minutes with a mean of 9.29 (SD±3.93). 
The duration of the fourth stage, administration of 
chemotherapeutics, applied by nurses, ranged from 1.46 
to 21.50 minutes with a mean of 4.12 (SD±2.77 minutes). 
The only material considered for the calculation of direct 
costs related to the 60 observations were examination 
gloves, with an average value of R$ 0.40. 
There was variation in the cost of direct labor of 
nurses between R$ 1.34 and R$ 19.78 with an average of 
R$ 3.79 (SD±2.55). The average total cost relating to this 
stage was R$ 4.19 (SD±2.55), and 90.45% with labor and 
materials with 9.55%. 
The duration of the last stage of venous access and 
disposal of chemotherapeutic wastes ranged from 2.05 to 
8.00 minutes for nurses (51 observations), with a mean of 
4.42 (SD±1.50) and 2.47 in 6.20 minutes for nursing tech-
nician (nine observations), with a mean of 3.71 (SD±1.39).
Table 3 – Distribution of observations relating to the removal of 
vascular access and disposal of chemotherapeutic wastes accor-
ding to duration, personnel costs, materials, solutions and drugs 
- São Paulo, SP, Brazil, 2013
Observations n Mean SD± Min Max Mode 
Direct labor cost   –   
preparation 60 5.22 1.79 1.17 10.55 ...
Direct labor cost   – 
administration 60 6.37 3.82 1.49 22.08 ...
Direct labor cost – 
Total (preparation 
and administration) 
60 11.59 4.67 5.15 28.92 ...
Materials’ cost 60 37.39 13.79 17.39 76.61 25.17
Solutions’ cost 60 4.47 1.77 1.46 7.02 2.92
Drugs’ cost 56 47.1 55.07 4.54 205.36 28.54
Total Cost 60 97.41 58.13 26.29 278.47 ...
1 One Real (R$) corresponded, at the time this paper was written (July of 
2014), to U$ 0,45 American cents.
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 Considering the five stages of the process, there was 
variation in duration from 25.52 to 78.29 minutes with a 
mean of 41.98 (SD±8.99). The average total duration of 
outpatient drug treatment to women with breast cancer, 
with the participation of pharmaceutical professional, 
pharmacy assistant, nurses and nursing technician, was 
41.98 minutes (SD±8.99).  
monotherapy for one year. However, such values  are very 
significant for countries such as Brazil, where health re-
sources are scarce, access to mammography is precarious 
and the diagnosis of breast cancer is late(9). 
By analyzing the flow of patients treated with breast 
cancer in public hospitals and employed by SUS, accord-
ing to the type of treatment received, authors(10) showed 
that the service was widely distributed throughout the 
country, with a strong concentration in the larger cities, 
but with evidence of lack of care even in regions where 
the supply of services was higher. We highlighted as a 
challenge to be faced the uneven distribution of popu-
lation and health services in the country and observed 
that in tertiary care, the concentration of diagnostic 
and therapeutic resources imposed extensive shifts to 
a considerable portion of the population, for example, 
a large proportion of patients lived more than 150 kilo-
meters from the service location. It was found that ap-
proximately half of the municipalities had not submitted 
any patient for breast surgery in the public network and 
partner with SUS, 17.8% did not referr women for che-
motherapy and 49% for radiotherapy(10). 
It is clear that women with breast cancer, besides ex-
periencing physical and emotional changes associated 
with the disease, need to face disparities in access to 
health care, which is connected to economic constraints. 
Thus, considering the demographic, epidemiological 
and sociocultural distribution of cancer in Brazil, associat-
ed with economic factors of the population, we agree that 
the systematic articulation of care in Oncology, in situa-
tions of poverty and low human development constitutes 
an important challenge for Nursing care(11). 
In relation to the materials used in the first stage, the 
Neutrapur equipment had the highest cost due to its spec-
ificity of infusion of certain drugs which, in contact with 
plastic polyvinyl chloride (PVC), caused detachment of 
plasticizer of di-2-etilexilftalato. To ensure patient safety, 
avoiding its exposure to this material, it is recommended 
the use of bags and catheters of polyolefin plastics (poly-
ethylene or polypropylene)(6). 
In the second stage - disposal pre-medications - the 
lowest average total cost obtained was related only to the 
cost of direct labor of the pharmacy assistant. 
The costs with curved needles, used to puncture the 
port-a-cath and venous catheter Intimates®, were high-
lighted when compared to the other materials used in 
the third stage. In some cases, this device can be imple-
mented before the start of treatment, however, in oth-
ers, their implementation occurs during treatment, while 
many women have increasing difficulty of venous access, 
due to the constant use of the peripheral venous infusion 
network of chemotherapy. Decadron 10mg and Ondas-
entrona 8mg were the most used pre-medications, how-
ever, the Palosentrona, even though it was the least used 
Table 4 – Distribution of observations relating to all stages of 
drug treatment under personnel costs, materials, solutions and 
drugs - São Paulo, SP, Brazil, 2013
Observations n Mean SD± Min Max Mode 
Direct labor cost   –     
preparation 60 5.22 1.79 1.17 10.55 ...
Direct labor cost   – 
administration 60 6.37 3.82 1.49 22.08 ...
Direct labor cost – 
Total (preparation and 
administration) 
60 11.59 4.67 5.15 28.92 ...
Materials’ cost 60 37.39 13.79 17.39 76.61 25.17
Solutions’ cost 60 4.47 1.77 1.46 7.02 2.92
Drugs’ cost 56 47.1 55.07 4.54 205.36 28.54
Total Cost 60 97.41 58.13 26.29 278.47 ...
diScUSSion 
During the period of data collection, the performance 
of chemotherapy regimens Paclitaxel, Doxorubicin + Cy-
clophosphamide, Trastuzumab and CMF, which are cited 
in the literature(5) as the most used in the treatment of 
breast cancer. The regimens FDC and FEC were not ob-
served, due to the low occurrence of its prescription. 
Trastuzumab, Paclitaxel and Doxorubicin + Cyclophos-
phamide were the most important drugs for the compo-
sition of the total average cost of the initial stage of the 
process - separation, preparation and disposal of chemo-
therapeutics, being the first of higher in unit value (R$ 
8,441.67). American study(4) showed that in a 18 month 
period, medical costs of care for women with metastatic 
breast cancer were, on average, U$ 128.556 dollars per 
patient. In the composition of total costs, the non-che-
motherapy drugs and chemotherapy drugs accounted for 
26% and 25% respectively, showing the significance of ex-
penditures on drugs. 
Note that Brazilian study indicated the economic point 
of view, which restrict the use of Trastuzumab to admin-
istration of chemotherapy for early stages would benefit 
from up to nine times more patients than monotherapy 
for one year, as used in other protocols. For this compari-
son, if translated in economic terms, the need to prevent 
a single value clinically significant outcome: recurrence of 
breast cancer after three years. Expenses with drugs to 
prevent a single case of recurrence accounted to just over 
R$ 418.000,00 in the most favorable scenario (Trastu-
zumab concomitant to initial chemotherapy cycles), and 
between R$ 1.7 to 3.9 million reais with Trastuzumab 
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pre-medication, represented the most significant drug in 
the composition of costs. 
In cancer therapy, acute emesis is controlled with the 
combination of drugs, the choice depends on the expected 
intensity in accordance with the drugs used in chemother-
apy. The degree of emesis of these drugs is given accord-
ing to the incidence of nausea and vomiting associated 
with their use(12). It is noteworthy that the pharmaceutical 
industries have developed very effective antiemetics and 
a longer duration of action but with higher costs, proving 
why the drugs Zofran and Palosentrona presented sizable 
values  for the average total cost of this stage of treatment. 
In the third stage - administration of pre-medications 
- the time spent by nurses for puncture of the port-a-cath 
was longer. This type of catheter is common in the chemo-
therapy infusion, disposal dressings and frequent heparin-
izations, being even less susceptible to infection and less 
prone to accidents such as breakage, corrosion and perfo-
ration(6). Therefore, due to the specificity and complexity 
of this type of access, the average time spent is justified 
by nurses to be higher (9.29 minutes) compared to the 
nursing technician (5.87 minutes), which had only a pe-
ripheral venipuncture. 
Study(13) developed in a Central Chemotherapy clinic, 
using the Nursing Intervention Classification(14), showed the 
time spent of 5.8 minutes to puncture the port-a-cath, which 
was mapped as an Intervention 2440 keeping device for ve-
nous access and 6.3 minutes for venipuncture performed by 
nurse (Intervention 4190 – venipuncture access). 
It is noteworthy that, in the control of tissue perfusion, 
better skills of nurses for the selection of site for veni-
puncture have been required, ensuring greater safety in 
the use of anticancer drugs(13). In this direction, the Out-
patient field of study, when the nurse notice a problem in 
relation to venous access, she/he notifies the oncologist 
responsible for the patient and, together, decide whether 
there is an indication of the implementation of central ve-
nous catheter. 
In the fourth stage - administration of chemothera-
peutics - as expected, because it is an exclusive activity 
of nurses, the cost of the direct labor in this category was 
the most important variable in the composition of average 
total cost. 
In the fifth step - the withdrawal of venous access and 
disposal of chemotherapeutic wastes - the anticoagulant 
heparin was the item that were highlighted in relation 
to costs. The mean duration of the vascular access and 
disposal of chemotherapy waste, which could be made 
by both nurses and nursing technicians, in the case of 
peripheral venous access, it was higher for nurses. This is 
because the withdrawal of the central line is the specific 
activity of the nurse, who before doing it, they perform 
the heparinization of port-a-cath, resulting in a longer 
time of action. 
Finally, the average total cost per chemotherapy ses-
sion, comprising the five stages of the process, corre-
sponded to R$ 1,783.01, being the cost related to drugs 
(93.75%) the most important cost.
The majority (58.33%) of the observations corre-
sponded to women from the Outpatient Unit for Social 
Sustainability. According to information obtained from the 
management of the Hospital Financial Sector, investment 
related to the comprehensive evaluation of these women, 
through the Integrated Program for Breast Cancer Con-
trol, which is reversed in the tax exemption. 
Regarding patients with health insurance, the Hos-
pital open a separate account to the individual in order 
to document all services and items used to subsidize the 
bill. Payment from patients with health insurance is de-
termined contractually, being set different fees for the 
services, together with the values  of materials and drugs, 
composing the total value of chemotherapy. 
The transfer of monetary values  of SUS to institutions 
which have chemotherapy for breast cancer in outpatient 
service can be established through contracting, setting 
agreed and formalized relationships between managers 
and providers of health services, or from the values  of 
SIGTAP (System List of Procedures Management, Medi-
cines, Prosthetics and Orthotics, and Specialty Materials 
- OPM of SUS)(15). 
It was not possible to compare the results of the study 
to the Table of procedures from SUS, because informa-
tion regarding the staging of the disease in many patients 
was not obtained, since they arrived at the Outpatient 
only with a medical prescription, because they have been 
referred by external physicians. However, the average to-
tal cost with respect to the stages studied (R$ 1,783.01) 
indicates that if the transfer occurred through this table, 
the values  for trading would be related to chemotherapy 
of advanced breast carcinoma 1st (R$ 1,700.00) and 2nd 
(R$ 2,378.90) lines. 
It is evident that the Ordinance Nº. 1.703/GM(16), when 
providing information for the allocation of resource to 
encourage contracts of Teaching Public and Private Hos-
pitals, presupposes a set of strategic actions, including:. 
Defining the care profile; the role of the institution and its 
insertion articulated and integrated with the network of 
SUS health services; and to define the responsibilities of 
hospitals and managers in continuing education and train-
ing of health professionals and qualification process for 
hospital management, because of the demands and the 
insertion of the hospital in regionalized and hierarchical 
network of SUS.
According to Ordinance Nº 1606/GM(17), the manager, 
state or municipal, may adopt different values  of the Pro-
cedure Table of SUS, but not below the permitted values 
which were determined by them to pay for health ser-
vices, provided that the difference is complemented with 
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state and/or municipal resources, being forbidden the use 
of federal funds for this purpose. 
A major challenge in conducting this study was the 
fact that similar studies have not been found in the litera-
ture, which did not allow comparison and discussion of 
the results. 
We also recognize the indispensability of costs of the 
stage supervision of nurses during infusion of chemother-
apy and its lack of observation constituted a limitation 
of this study. Thus, in an attempt to estimate the value 
of direct labor to be added to the average total cost per 
chemotherapy session, we identified as R$ 1,783.01, a 
meeting with the nurses in the Outpatient Chemothera-
py was held and they, from their experience and clinical 
experience, reached the consensus that the duration of 
infusion Paclitaxel, CMF, Doxorubicin and Cyclophospha-
mide + Trastuzumab corresponded to two hours and 30 
minutes, two hours, one hour and 30 minutes and one 
hour, respectively. 
To estimate the average increase in direct labor, the 
presence of three nurses at the Clinic was considered, on 
a daily journey of eight hours of work in order to assist 
an average of ten patients undergoing chemotherapy, re-
gardless of the antineoplastic regimen or combination of 
drugs. This decision was based on variability in prescrip-
tion of anticancer regimens or combinations of drugs and 
the need to include the daily cost of these professionals. 
Then, the number of nurses was multiplied by the num-
ber of patients per day (3 x 8 x 54.92 = R$ 1,318.08 / 10) to 
give the average increase of R$ 131.81. 
It is believed that the study results will assist in the 
verticalization of discussions of the cost of outpatient 
drug treatment of women with breast cancer, especial-
ly with regard to the reasoning of the professionals in-
volved, with the choice, acquisition and criteria use of 
materials needed. 
Such discussions may facilitate the acquisition and 
sharing of new knowledge, providing reflections among 
health professionals about ways of funding SUS and the 
SHS, the costing methods and principles of strategic cost 
management, broadening the perspective on the eco-
nomic factors involved in the care process. 
By addressing clinical and economic aspects of adju-
vant chemotherapy in HER2-positive breast cancer, the 
authors claim that the medical profession and society 
should pay attention not only to the eligibility criteria or 
differences in efficacy between the various treatment pro-
tocols in use, but also, the economic implications of indi-
vidual therapeutic decisions for the health care system(9). 
Knowing the cost of pharmacological treatment gener-
ated by this study can provide the professional nursing staff, 
especially the nurses coordinators and care providers, ele-
ments to rethink their practice, since they are in continuous 
contact with these patients and therefore have a privileged 
position to assess their real demands of care to the avail-
able resources, assisting in cost containment. 
It is reiterated that the rising costs related to antineo-
plastic therapy have been established in the focus of at-
tention of the managers of public and private health sys-
tems in order to find alternatives to reduce them. Cost 
management is, therefore, a key tool for resource control, 
to help identify more effective and strategic ways to pro-
vide administrators the opportunity to identify the most 
profitable activities, as well as those whose cost need to 
be analyzed and controlled with utmost care, or activities 
that are not economically viable(18). 
In this view, the professionals who manage hospitals 
need to develop skills that help them in decision making 
and resource allocation. To do so, they must determine 
what resources are needed for the production level of as-
sistance or support from their workplace activities, con-
sidering the quantitative/qualitative aspects and adding 
financial aspects(19). 
We agree that the identification of the costs of health 
services reveals which sectors and actions need to be in-
creased in order to reduce costs, eliminating waste effi-
ciently and preserving the quality of care provided(20). 
Finally, we emphasize the importance of the nurse as 
responsible for the management of materials and their 
costs in hospitals, as knowledge and means holder for 
making decisions relating to the care process, based on 
scientific evidence to support its arguments in relation to 
the need for spending across the various types of treat-
ment and justify the allocation of human resources to the 
administration(21). 
Knowing the modes of funding, identifying and monitor-
ing elements and process steps that increase costs and that 
can be removed without loss of quality and without compro-
mising demands, nurses can improve the performance of 
health institutions. However, while the economics aspects 
are important, it should not, under any circumstances, over-
lap technical, ethical and social aspects of human care (22). 
concLUSion
The average total cost per session of an outpatient 
chemotherapy clinic for women with breast cancer was 
R$ 1,783.01 (100%), of which R$ 1,671.66 (93.75%) with 
drugs, R$ 74.98 (4.21%) with materials, R$ 28,49 (1.60%) 
with direct labor and R$ 7.88 (0.44%) with solutions. 
Considering the specificity of supplies involved in the-
se procedures, it becomes fundamental for nurses, who 
conducts and supervise much of the therapeutic process, 
the management of costs, especially due to its high eco-
nomic impact for public and private health systems.  
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